Amycretin and the Quiet Return of Amylin

Novo Nordisk folded two gut-hormone signals into a single peptide. The early numbers — and the fact that they keep climbing — explain why the field is watching.

The obesity story has, until now, been a GLP-1 story. Amycretin — recently given the generic name zenagamtide — argues that the next chapter belongs partly to amylin, a hormone the pancreas releases alongside insulin to signal that a meal is finished. Novo Nordisk built amycretin as a single engineered peptide that switches on both the GLP-1 and the amylin receptor at once, a design the field calls unimolecular.

That word is the point. Rather than combine two separate drugs, amycretin is one molecule doing two jobs — and Novo made it in two forms: a once-weekly injection and a once-daily pill.

The numbers that made researchers look twice

In its early obesity work, first reported in The Lancet and expanded through 2025, injectable amycretin produced weight loss of roughly 9.7% at twenty weeks, near 16% at twenty-eight weeks, and about 22% at thirty-six weeks. The shape of that curve mattered more than any single figure. There was no obvious plateau — the line was still bending downward when the readout ended, which is the detail pharmacologists chase.

In November 2025, the company reported its first results in type 2 diabetes, and in June 2026 it presented fuller data at the American Diabetes Association’s Scientific Sessions in New Orleans. Across 262 patients, the highest dose lowered A1C by up to about 1.8 points from a baseline near 7.8%, and drove weight down by as much as roughly 14.6% over thirty-six weeks, against about 2% on placebo. Side effects were the class-typical gastrointestinal ones — nausea, reduced appetite — mostly mild to moderate.

Why amylin, and why now

Amylin is not new. Pramlintide, the first amylin analog, has been available since 2005 and is used sparingly in the treatment of diabetes. What changed is the understanding that amylin and GLP-1 act on overlapping but distinct brain circuits governing appetite — the hypothalamus and hindbrain among them — and that hitting both can deepen fullness beyond what either does alone.

Novo is pursuing that thesis on two fronts. One is CagriSema, which pairs semaglutide with the amylin analog cagrilintide as separate molecules in one injection. The other is amycretin, which collapses the same two-receptor strategy into a single peptide. The unimolecular approach promises simpler manufacturing and cleaner dosing, if the biology holds.

The stakes for Novo Nordisk

The context is a company under pressure. Novo spent 2025 trimming forecasts, weathering a boardroom shake-up, watching an Alzheimer’s bet fail, and losing a high-profile acquisition to Pfizer. Amycretin is the asset analysts keep circling — the molecule Novo intends to fight with next.

The company has said it plans a broad phase 3 program in 2026 spanning both obesity and diabetes, in injectable and oral forms. The question is not only whether amycretin can post a big number. It is whether it can deliver deep, durable weight loss that patients tolerate for years, in a market where retatrutide and CagriSema have already raised the bar.

What it means

Amycretin will not be measured against placebo in the public mind. It will be measured against the best of its rivals — and against the tolerability ceiling that limits how much of any of these drugs people can actually take. The early data are genuinely strong, and the absence of a plateau is the most interesting thing about them. Phase 3 will decide whether amylin’s return is a headline or a footnote.

For now, the quiet hormone is having a loud year.

Frequently asked questions

What is amycretin? Amycretin (generic name zenagamtide) is a Novo Nordisk drug candidate: a single engineered peptide that activates both the GLP-1 and amylin receptors at once — a design called unimolecular. It comes in once-weekly injectable and once-daily oral forms.

Is amycretin better than Wegovy? It is too early to say definitively, since amycretin is still in development. Early trials showed injectable amycretin producing roughly 22% weight loss at 36 weeks with no clear plateau — encouraging numbers, but not yet from the large phase 3 trials needed for a fair comparison.

When will amycretin be available? Novo has said it plans a broad phase 3 program starting in 2026 across obesity and diabetes. Approval, if the data hold, would follow the completion of those trials — realistically several years out.

Sources

1. Novo Nordisk A/S — press releases on amycretin subcutaneous and oral obesity trials (2025) and phase 2 type 2 diabetes results (November 2025).
2. American Diabetes Association — 86th Scientific Sessions, New Orleans, June 2026 (amycretin/zenagamtide diabetes data presentation).
3. The Lancet — amycretin phase 1 obesity results, 2024–2025.
4. Pharmacy Times and Clinical Trials Arena — coverage of amycretin trial data, 2025–2026.
5. Novo Nordisk pipeline and R&D disclosures, 2026.